SOD1
Assets acting on this target.
- Class
- SOD1 mRNA-lowering oligonucleotide (antisense or RNAi)
- Notes
- mechanism wave 2026-08-24 (DeepSeek draft; registry text of NCT06351592 names the target); source: https://clinicaltrials.gov/study/NCT06351592
By indication
SOD1 drugs compared
2 drugs, stage by indication
| Drug | Developer | Modality | Furthest stage | Stage by indication |
|---|---|---|---|---|
| TofersenQalsody | Biogen, Ionis Pharmaceuticals | antisense | Approved | Approved in Amyotrophic Lateral Sclerosis |
| ALN-SOD | Regeneron Pharmaceuticals | RNAi (siRNA) | Phase 1/2 | Phase 1/2 in Amyotrophic Lateral Sclerosis |